FDA chief scientist Steven Kozlowski said the agency plans to expand its Focus Areas of Regulatory Science (FARS) update to include aging and longevity medicine, aiming to define shared, pre-competitive endpoints for biological and clinical measurement. The FDA framed the effort as a bridge to help feasible clinical trial designs and improve accessibility. The announcement signals regulatory attention to healthspan as a therapeutic development domain, with implications for how trials are structured and evaluated.